Thanks for weighing in on TGTX. Just to be clear: There won’t be a generic Rituxan available in any market during the next several years; rather, there will be (and already are in some markets) non-interchangeable Rituxan FoBs that have to be marketed as distinct branded drugs and have relatively high prices. For new CD-20 entrants, this is clearly a better scenario than having to compete against a full-fledged Rituxan generic.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.